In the era of immune-oncology research, the incorporation of traditional immunohistochemistry (IHC) approaches has been used as a biomarker screening tool. Recently, though, an increasingly complex interplay between tumor cells and the tumor immune microenvironment has been revealed, indicating that single data points provided by IHC are not sufficient to provide the granular level of data needed, not only for discovery, but for patient stratification for targeted therapies and insight into clinical responses, especially with the growing need for the identification of new biomarkers predictive for sensitivity to current anti-PD1 and anti-PDL1 therapies.

Following on from last year’s success, we are thrilled to announce that the 2^nd Biomarker Insights Summit hosted by Ultivue returns, in-person, to highlight the challenges and opportunities of identifying and validating biomarkers in the immune-oncology arena, together with exploring how innovative digital pathology insights afforded by multiplex immunofluorescence techniques can provide benefit to clinical trials.

This summit will help define the new wave of the tissue biomarker industry through exclusive discussions with the movers and shakers, focusing on how evolving digital pathology workflows and the use of multiplex immunofluorescence can improve validation of protein and RNA biomarkers in situ when evaluating clinical utility of compounds of interest, as well as the strategies surrounding the implementation and use of digital pathology, AI and digital image analysis.

This is your chance to be at the heart of the discussion by joining 100+ of your peers to accelerate the translation of predictive biomarkers into the reality of healthcare!